Why Ocular Therapeutix Inc Stock Jumped Higher Today

What happened

Ocular Therapeutix (NASDAQ: OCUL)stock is up 9.7% as of 11:41 a.m. EDT after the company presented phase 3 data for eye pain drug Dextenza.

So what

We already knew the clinical trial was successful and the company released quite a bit of data in January, but nevertheless, it's always helpful to see data presented in front of doctors who will be using the product.

More From Fool.com

Motley Fool Founders Issue New Stock Buy Alert

Forget GE! Heres how to play the largest growth opportunity in history

Forget Apple! Heres a Better Stock to Buy

He Made 21,078% Buying Amazon. Heres His New Pick

In Ocular Therapeutix's presentation at the American Society of Cataract and Refractive Surgery Annual Symposium, Dextenza met its primary endpoints of the absence of anterior chamber (AC) cells, which is a sign of inflammation, on day 14 and the absence of pain on day 8. More than 52% of patients that got Dextenza after cataract surgery had no AC cells on day 14 compared to 31.1% patients that got placebo. The pain reading was also superior, with 79% of patients who took Dextenza reporting no pain on day 8 compared to 61.3% of patients that took placebo.

Some of today's increase in share price could also be because investors have decided that the issues at the company's manufacturing plant identified by the FDA can be resolved relatively quickly, so Friday's decline wasn't completely justified.

Image source: Getty Images.

Now what

Today's data was a useful step forward, but investors should be focused on the potential approval of Dextenza. Ocular Therapeutix has already submitted the marketing application for Dextenza to the FDA, which is expected to make a decision by July 19.

Assuming Ocular Therapeutix can resolve the manufacturing issues in a timely manner, the company looks like it's in good shape to receive an approval in a couple of months.

10 stocks we like better than Ocular TherapeutixWhen investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Ocular Therapeutix wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of May 1, 2017

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.